Kent Mouw, Radiation oncology physician-scientist at Dana-Farber Cancer Institute, shared a post on X about a paper he co-authored with colleagues published in Clinical Cancer Research:
“Happy to share new work from our team now available online in Clinical Cancer Research. We profiled plasma ctDNA dynamics in patients with muscle-invasive bladder cancer (MIBC) treated with bladder-sparing trimodality therapy (TMT)…
Although ctDNA dynamics are correlated with therapy response and outcomes in metastatic disease and in patients treated with radical cystectomy, there is a paucity of data in the TMT space. To address this gap, we profiled a series of >80 TMT patients treated at our centers…
Our take-home finding is that ctDNA detectability was strongly correlated with metastatic – but not local – disease recurrence. A big thanks to patients, families, research teams, colleagues, and funding sources who made this work possible!”
Title: ctDNA dynamics and recurrence patterns after organ-sparing trimodality therapy for bladder cancer
Authors: Ilana B. Epstein, Adetolani Odogiyon, Stephanie Berg, Yukako Otani, Charlene Mantia, Isabella R. Pompa, Matthew Mossanen, Joshua Wan, Anurag Saraf, Mark Preston, Arvind Ravi, Filipe Carvalho, Cameron Herberts, Adam ElNaggar, Timothy Clinton, Daniel Roberts, Luke Peng, Bradley McGregor, Joaquim Bellmunt, Sophia C. Kamran, Jacob E. Berchuck, Jason A. Efstathiou, David T. Miyamoto, and Kent W. Mouw
You can read the Full Article in Clinical Cancer Research.
More posts featuring Kent Mouw.
